Contrasting Cascadian Therapeutics (CASC) & Its Rivals
Cascadian Therapeutics (NASDAQ: CASC) is one of 292 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Cascadian Therapeutics to related businesses based on the strength of its risk, dividends, analyst recommendations, earnings, valuation, institutional ownership and profitability.
Institutional and Insider Ownership
82.6% of Cascadian Therapeutics shares are owned by institutional investors. Comparatively, 51.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 1.1% of Cascadian Therapeutics shares are owned by company insiders. Comparatively, 16.3% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This is a summary of recent recommendations and price targets for Cascadian Therapeutics and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cascadian Therapeutics Competitors||750||2998||11105||224||2.72|
Cascadian Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 41.18%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 32.74%. Given Cascadian Therapeutics’ higher probable upside, research analysts plainly believe Cascadian Therapeutics is more favorable than its peers.
This table compares Cascadian Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cascadian Therapeutics Competitors||-5,560.76%||-448.09%||-42.01%|
Risk and Volatility
Cascadian Therapeutics has a beta of 2.32, meaning that its stock price is 132% more volatile than the S&P 500. Comparatively, Cascadian Therapeutics’ peers have a beta of 6.62, meaning that their average stock price is 562% more volatile than the S&P 500.
Valuation & Earnings
This table compares Cascadian Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Cascadian Therapeutics||N/A||-$47.29 million||-2.64|
|Cascadian Therapeutics Competitors||$261.64 million||$67.77 million||-7.02|
Cascadian Therapeutics’ peers have higher revenue and earnings than Cascadian Therapeutics. Cascadian Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Cascadian Therapeutics peers beat Cascadian Therapeutics on 7 of the 12 factors compared.
Cascadian Therapeutics Company Profile
Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company’s ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.
Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.